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ABSTRACT 
To develop a more efficient way of informing potential clinical trial volunteers of exactly 
what they could expect during (and after) their participation in a clinical trial as well as 
the sponsor’s expectations from the volunteer.  
A multiple choice questionnaire, which was based on the criteria as specified by 
Guideline 5 of the International Conference of Harmonization (ICH), was administered to 
28 Volunteers after only reading the Patient Information Leaflet/Informed Consent 
Document (PIL/PIL/ICD), to 21 Volunteers who had read the PIL/ICD and attended a 
question and answer session, to 17 Volunteers who had read the PIL/ICD and attended a 
presentation and 19 Volunteers who had read the PIL/ICD and attended a presentation 
and a question and answer session.  In total, 85 Volunteers completed the questionnaire. 
The average calculated percentage* of volunteers who had only read the PIL/ICD was 
61%, 63% for Volunteers who had read the PIL/ICD and attended a question and answer 
session, 73% for Volunteers who had read the PIL/ICD and attended a presentation and 
68% for Volunteers who had read the PIL/ICD and attended a presentation and question 
and answer session. In total, the average calculated percentage was 66%.  Eighty four 
percent of the total number of volunteers answered the question on withdrawal 
consequence incorrectly, 43% of Volunteers answered questions on side effects 
incorrectly and 100% of the Volunteers answered the question on the duration of storage 
of samples incorrectly. 
Despite increasing regulatory and ethical scrutiny, deficiencies still exist in Volunteer 
comprehension of the research in which they participate, as well as differences in how 
comprehension is measured and assessed.  Results indicated that any successful consent 
process should, at a minimum, include a visual communication mode. Concepts that are 
not well understood within the South-African context are withdrawal consequence, 
methodology such as double-blind or single blind, side effects, duration of archiving, 
treatment alternatives and the role of the investigator. 
*calculated % for each volunteer = score out of 25 x 100 
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ABBREVIATIONS 
  
ADR Adverse Drug Reaction 
CIOMS Council form International Organizations of Medical Sciences 
EMEA European Medicines Agency 
IC Informed Consent 
ICD Informed Consent Document 
PIL/ICD Patient Information Leaflet/ Informed Consent Document 
ICH International Conference of Harmonization 
ICU Intensive Care Unit 
PIL Patient Information Leaflet 
SOP Standard Operating Procedure 
  
DEFINITIONS 
Investigator 1.) One or more persons responsible for the practical performance of a trial 
and for the integrity, health, and welfare of the subjects during the clinical 
study. The individual(s) who actually conducts the clinical investigation and 
under whose immediate direction drug is administered or dispersed to a 
subject. 
2.) A person responsible for the conduct of the clinical trial at a trial site.  If 
a trial is conducted by a team of individuals at a trial site, the investigator is 
the responsible leader of the team and may be called the principal 
investigator.  
PIL/ ICD 
(Patient 
Information 
Leaflet/ 
Informed 
Consent 
Document) 
The form prepared by the investigator and/or the sponsor, and approved by 
the Independent Ethics Committee, which must be signed by the subject 
before entry in a clinical trial. It is the legal written record that the subject, 
or his/her representative, agrees to voluntarily participate in the 
investigation. Also referred to as "consent form" or "subject consent form". 
Vulnerable 
Population 
Any circumstances in which volunteers are in a position of dependency 
(research volunteers, elderly, indigenous, poor people, illiterate people, 
dying volunteers) make them potentially vulnerable 15 
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CHAPTER 1: INTRODUCTION 
 
1.1  Introduction 
Following the TeGenero (TGN 1412) Phase I trial in April 2006 where six volunteers 
nearly died due to unexpected Adverse Drug Reactions (ADR), the informed consent 
(IC) process received renewed attention.  
Volunteers claimed that they where not aware of the potential danger of the trial despite 
an elaborate IC process.  The volunteers claimed that the IC process was not thorough 
enough and was performed in haste.  Investigations into the matter proved the contrary 
and that the staff that administered the IC was not at fault. 
This raises the question: How informed are volunteers? 
Nirmala Bhogal, science manager at the Fund for the Replacement of Animals in 
Medical Experiments, argues that people will now be more demanding about the data 
they are given before they take part in trials. “Healthy people will probably now be 
unwilling to volunteer unless they are given more information,” she says. “Perhaps 
volunteers should be shown all the available data and allowed to make their own 
judgments” 1. 
Regardless of the potential risks and dangers of clinical trials, they are still essential for 
the progress of medicine.  
In recent years there has been a shift in thinking by volunteers and professionals alike: 
volunteers should be involved in decisions about their own care. However, we have not 
yet seen a change in volunteer’s involvement as proven by numerous studies mentioned 
below. Volunteers still rely on their healthcare providers to provide the “best” care 
without paying much attention to what they are being told, and thus, placing their trust 
in their healthcare providers during the decision making process. 
A major concern is that the medical research being conducted in third world countries 
is often sponsored by first world countries.  South-Africa is particularly attractive for 
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clinical research because of a large population, modern medical facilities and low per 
capita income. This necessitates the need for a valid informed consent.  
 
Although it is clear that there are warning signs regarding volunteer’s comprehension in 
both “developed” and “developing” communities in South-Africa, there has been very 
little investigation conducted into how to actually address this problem.  
 
Furthermore, there is often a great difference between the readability of the PIL/ICD 
and the volunteers’ understanding of it. Although the volunteer’s understanding and 
recall of the words used may be readily tested, comprehension of the concepts involved 
(e.g. benefit-to-risk ratio) are difficult to measure even in controlled settings 2. 
 
In an online survey conducted by CenterWatch in January & February of 2002, a 
surprising amount of volunteers (14%, n=1561) reported that they had signed the 
Informed Consent without even reading the form.  “The form was Greek to me; and no 
one really explained anything. They handed me the papers and gave me a lot of time to 
look them over. I just asked a few questions, then went ahead and signed it. I didn’t 
worry because I knew that I could pull out of the study at any time. I felt safe enough”3. 
 
Another volunteer disagreed: “Study staff wanted to make sure I knew exactly what the 
terms in the form meant. They explained everything very well and told me about the 
risks and side effects. They kept reminding me that if I had any questions I could call 
them at any time” 3. 
The majority of volunteers (86%) indicated that they had read the Informed Consent 
prior to signing it.  
The following results were found regarding volunteer comprehension & understanding 
of study design 3: 
 
 Page 3  
    
 
 
Figure 1: Volunteer Comprehension: percent of study volunteers 
 
Figure 2: Volunteer Understanding of Study Design: percent of study volunteers 
Numerous guidelines have been developed in recent years on exactly what information 
should be shared with prospective volunteers in clinical trials. These include local 
requirements as well as global recommendations. Globally, the “Gold Standard” 
 Page 4  
    
 
guidelines are provided by the Declaration of Helsinki (2003) and the International 
Conference of Harmonization (ICH). 
 
The Declaration of Helsinki requires the following information to be disclosed within 
the PIL/ICD: 
 
o The study’s aims and methods 
o Sources of funding and possible conflict of interests 
o The researcher’s institutional affiliations 
o Anticipated benefits and potential risks and the follow-up of the study 
o Discomfort that trial participation may entail 
o Right to abstain from participation in the study, or withdraw from it at any time 
without any reprisals (World Medical Association. Declaration of Helsinki. 
2003) 
 
Bert Spilker has recommended the following methods to increase the level of a volunteer’s 
comprehension about a clinical trial2: 
 
A. Writing the PIL/ ICD 
 1.  Use words of one or two syllables whenever possible 
 2. Use short declarative sentences 
 3. Avoid legal phases 
 4. Follow a format that leads the volunteer logically through all parts of the 
clinical trial 
 5. Explain scientific terms and words in lay language (e.g. “test to look at 
brainwaves” instead of EEG2. 
   
B. Evaluating the PIL/ ICD 
 1. Assess the readability with a standard scale (e.g. Flesch Fry) 
 2. Assess the comprehension by having nontrial volunteers read and critique 
the PIL/ ICD 
 3. Assess connotations of words used to ensure that volunteers are not 
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mislead2 
   
C. Counseling the volunteer 
 1. Review the overall nature of the clinical trial with each volunteer before 
they read the form 
 2. Have group question-and-answer sessions of several volunteers and 
supply background information 
 3. Have the volunteers keep the form for at least 12-24 hours before they 
are requested to sign 
 4. Repeat some or all aspects of the informed consent procedure during the 
trial 
 5. Have another volunteer advocate clarify issues with the volunteer2 
   
D. Other 
 1. Provide counseling to the volunteer’s family 
 2. Divide the process into two parts, by which the second is done on a 
different day and confirms that the volunteer still desires (or is willing) to 
enroll and has no further questions 
 3. Have the volunteer explain to the investigator or another person to verify 
that the volunteer understands the nature of the clinical trial2 
 
1.2  Prior Studies 
Several studies conducted in both Europe and North America have assessed the degree 
of comprehension of the informed consent process, and have illustrated flaws in 
comprehension 4.  
In a study 5 to analyze the procedure of informed consent for Intensive Care Unit (ICU) 
research obtained before ICU admission showed that as many as 22% of ICU 
volunteers who consented to participate in a study were unable to recall their 
participation in the study, although they had provided their consent prior to their 
admission, in a non-stressful environment (prior to elective admission).  
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The results of this study 5 can be summarized as follows:  
 
 Figure 3: Intensive Care Unit study results5 
Among consenting parents in nine European countries 20.7% of parents misunderstood 
the concept of voluntary withdrawal 6. A qualitative study in East Africa revealed 
common themes such as “…it is inappropriate to question a doctor”, and “…there are 
no risks to this study” amongst consenting volunteers 7. 
As a part of a study on the desired features in multimedia consent forms, Jamison 
et.al.14 asked 29 volunteers with potential cognitive impairments (depression, 
schizophrenia and breast cancer) to read a sample consent form and to suggest 
improvements to that form. These volunteers said that the consent form was too long, 
with too many complex words and confusing details. One must thus be aware that 
retention of information may be compromised by information overload. 
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The most insightful study regarding volunteer comprehension was conducted quite 
recently in Mali, West Africa by Krosin et.al. 20068 whereby a questionnaire 
containing nine questions was administered to assess volunteer comprehension 
regarding the following topics: 
1. Voluntary participation 
2. Compensation 
3. Withdrawal criteria 
4. Withdrawal consequence 
5. Study versus treatment 
6. Study administration 
7. Randomization and placebo 
8. Side effects 
9. Lay scientific knowledge8 
These questionnaires were administered to 163 rural and peri-urban volunteers. The 
results are as follows: 
• 43% answered the question on voluntary participation incorrectly 
• 56% answered the question on compensation incorrectly 
• 90% answered the question on withdrawal criteria incorrectly 
• 56% answered the question on withdrawal consequence incorrectly 
• 74% answered the question on study versus treatment incorrectly 
• 34% answered the question on study administration incorrectly 
• 32% answered the question on randomization and placebo incorrectly 
• 93% answered the question on side effects incorrectly (which bears 
critical ethical consequence) 
• 27% answered the question on lay scientific knowledge incorrectly 
Although these results are poor, it is likely that the percentages of correct answers 
observed are high relative to the population sampled. Thirty seven percent of the study 
population could not reliably use a multiple choice format and were ineligible for the 
survey 8. 
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The results of the above study should be viewed in context with other studies conducted 
in the industrialized world. 
In another study, 156 war veterans were interviewed to determine their degree of 
understanding of a clinical protocol for which they had signed a PIL/ICD. They were 
interviewed less than 10 weeks after signing: only 10% could totally describe the 
objective of the study 9. 
There are no studies available in South-Africa on how to improve the PIL/ICD process. 
1.3  Definition of “Informed Consent”  
Informed consent is defined by the International Conference and Harmonization11 as: 
“The process by which a volunteer voluntarily confirms his or her willingness to 
participate in a particular trial, after having been informed of all the aspects of the 
trial that are relevant to the volunteer’s decision to participate. Informed Consent is 
documented by means of a written, signed and dated PIL/ICD” 11. 
Informed consent is a decision to participate in research, taken by a competent 
volunteer who has received the necessary information; who has adequately understood 
the information; and who, after considering the information, has arrived at a decision 
without having been volunteered to coercion, undue influence or inducement, or 
intimidation10. 
Informed consent is based on the principle that competent volunteers are entitled to 
choose freely whether to participate in research. Informed consent protects the 
volunteer's freedom of choice and respects the volunteer's autonomy. As an additional 
safeguard, it must always be complemented by independent ethical review of research 
proposals. This safeguard of independent review is particularly important as many 
volunteers are limited in their capacity to give adequate informed consent; they include 
young children, adults with severe mental or behavioral disorders, and persons who are 
unfamiliar with medical concepts and technology10. 
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Obtaining informed consent is a process that is begun when initial contact is made with 
a prospective volunteer and continues throughout the course of the study. By informing 
the prospective volunteers, by repetition and explanation, by answering their questions 
as they arise, and by ensuring that each volunteer understands each procedure, 
investigators elicit their informed consent and in so doing manifest respect for their 
dignity and autonomy. Each volunteer must be given as much time as is needed to 
reach a decision, including time for consultation with family members or others. 
Adequate time and resources should be set aside for informed-consent procedures10. 
The investigator must then ensure that the prospective volunteer has adequately 
understood the information. The investigator should give each one full opportunity to 
ask questions and should answer them honestly, promptly and completely. In some 
instances the investigator may administer an oral or a written test or otherwise 
determine whether the information has been adequately understood 4. 
1.4  Steps to obtain informed consent 
There are several key elements of the IC process which requires the research team to 
share open and honest information regarding the clinical trial which in turn, can be 
easily understood by the volunteer and allows him/her to act upon this information10. 
 
Firstly, the research team has to provide transparent information in such a way that it 
can be easily understood. Aspects such as the nature of the sponsorship, benefits and 
risks of participation, and the responsibility for care and complications must be 
carefully explained. The volunteers must be given the opportunity to ask questions in 
order to clear ambiguities and obtain additional information10. 
 
The second step is critically important: the volunteer must understand what is asked of 
them 10. 
 
Lastly, the volunteer must freely agree to take part in the clinical trial. Therefore, not 
only must the volunteer understand the project but must be competent to give consent 
or decide to withdraw 10. 
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In conclusion, the cases above highlight that the process of informing volunteers of 
potential risks and benefits related to their participation in a clinical trial, is proving to 
be a difficult art to master. 
 
1.5 Legal Issues 
 
USA Today reported last year that the pharmaceutical industry “…faced the most 
product liability lawsuits of any other industry” 18. 
 
Lawsuits against pharmaceutical companies totaled 17 027 last year, more than all other 
industries with significant liability suits combined:  n = 3 236 (Manufacturing); 
n = 2 875 (Chemicals); n = 2 717 (Construction); n = 2 636 (Financial services) and n = 
1 926 (Insurance) 18. 
 
Recent years have seen an increase in lawsuits where the validity of the informed 
consent process has been questioned and in many cases found invalid. 
 
In the most recent case, Kano State Government versus Pfizer, 5 children died after 
they received an experimental drug named Trovan® for meningococcal meningitis, 
although there is no indication in the documents that the drug caused the deaths. Six 
children died after receiving the comparator drug, Hoffmann-La Roche's Rocephin® 
(ceftriaxone).  It was found that there were no consent forms (many parents of the 
children were illiterate) and no signatures from witnesses to confirm that parents 
understood that their children were taking part in an experiment. In fact, in certain 
reports it was stated that the parents were banned from entering the wards where their 
children were being treated. This trial is still ongoing. 
 
Another common theme amongst recent lawsuits is the failure to disclose conflict of 
interest. In the case of Jesse Gelsinger versus Genovo 17, it was discovered that  
Dr Wilson (the Principal Investigator) owned 30% of the shares in Genovo. 
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There are many more examples of lawsuits that have been concluded in favour of the 
plaintiff due to insufficiencies within the informed consent process or documents. Thus 
to ensure the protection of volunteers and that valuable research is not lost, more time 
should be invested into the improvement of this vital component of clinical research. 
 
Since there is an increased legal awareness of the validity of the Informed Consent 
process and documentation as seen in the Kano State Government versus Pfizer, it is 
imperative to ensure that this process is both ethical and legal. 
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CHAPTER 2: STUDY OBJECTIVES 
 
2.1 Aim 
The aim of this project was to develop an efficient method of informing potential 
clinical trial volunteers of exactly what they could experience during (and after) their 
participation in a clinical trial.  
2.2 Objectives 
 
(i) To compare the efficiency of data transfer to volunteers enrolled on a clinical 
trial by assessing their comprehension of clinical trial concepts 
(ii) To identify the most effective method of transferring data to volunteers 
intending to enroll into a clinical trial.  
2.3 Procedure 
 
Currently various methods are used to inform volunteers of the potential benefits and 
risks associated with their participation in a clinical trial (sometimes in various 
combinations): 
• Volunteers are provided with a copy of the PIL/ICD to read the day prior to the 
actual Informed Consent session 
• Group Question & Answer sessions 
• In depth PIL/ICD discussions 
• Presentations (although rarely used) 
 
To ensure that various combinations of the above mentioned methods were tested, the 
questionnaires were administered at various time points during the Informed Consent 
procedure: 
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Figure 4: Methods of data transfer 
 
There were four groups of volunteers: 
• Group 1: volunteers who had only read the PIL/ICD 
•    Group 2: volunteers who had read the PIL/ICD and attended the group 
question & answer session 
• Group 3: volunteers who had read the PIL/ICD and attended the presentation 
• Group 4: volunteers who had read the PIL/ICD, attended the presentation & 
attended the group question & answer session 
 
The four groups comprised out of volunteers participating in actual trials at the 
FARMOVS/PAREXEL facility during the last two years in the following indications: 
• Group 1: Human Immunodeficiency Virus (HIV) and Asthma trials 
• Group 2:  Human Immunodeficiency Virus (HIV) and Asthma trials 
• Group 3:  Alcohol addiction trial 
Read PIL/ ICD 
IC Questionnaire 
Question & Answer 
 
Sign Study PIL/ ICD 
Read PIL/ ICD 
Question & Answer 
 
IC Questionnaire 
Sign Study PIL/ ICD 
Read PIL/ ICD 
PowerPoint 
 
IC Questionnaire 
Sign Study PIL/ ICD 
Timing of Questionnaire administration 
Group 1 
Read PIL/ ICD 
PowerPoint Presentation 
IC Questionnaire 
Sign Study PIL/ ICD 
Question & Answer 
n = 28 n = 21 n = 17 
n = 19 
Group 2 Group 3 Group 4 
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• Group 4: Human Immunodeficiency Virus (HIV) , Asthma and Alcohol 
addition trials 
Due to logistical reasons it was not possible to distribute participants from these trials 
equally into each group. All procedures were standardized across the different trials. 
Please refer to APPENDIX IV for an example of the PIL/ICD used for these trials. 
 
Each volunteer was only allowed to participate once and be included into one group. 
Volunteers were assured that their participation was entirely voluntary and that the 
results of the questionnaire would be anonymised by assigning a questionnaire number 
only. No personal identifiers such as the volunteer’s name or initials were noted. 
Volunteers were also assured that the results of the questionnaires did not affect their 
eligibility for the prospective trial they were being screened for. 
 
Where a method of data transfer would normally be considered unethical such as only 
allowing a volunteer to read the PIL/ICD and then sign the consent form, the informed 
consent procedure was resumed after completion of the questionnaire.  
 
For instance, volunteers in group 1 had the opportunity to read the PIL/ICD and were 
then asked to complete the questionnaire. Upon completion of the questionnaire, they 
would then attend a question and answer session and the informed consent procedure 
would be completed as per the standard operating procedure of 
FARMOVS/PAREXEL.  
 
2.4 Informed Consent for this project 
 
A PIL/ICD was developed for this project. However, it was decided not to obtain 
Informed Consent to partake in this project as it would have introduced bias and thus 
would have unduly influenced the outcome of this project. Volunteers were verbally 
invited by the study physician to complete the questionnaire. It was explained to the 
volunteers that their results would in no way affect their eligibility and that the results 
would merely be used to improve current practices and procedures. 
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The volunteers did, however, sign the actual clinical trial’s screening and enrollment 
PIL/ICD’s as per the specific trial sponsor’s and FARMOVS/PAREXEL Standard 
Operating Procedures (SOP’s). These were then filed together with all other study 
related documentation on site.  
 
2.5 Questionnaire 
 
Guideline 5 of the International Ethical Guidelines for Biomedical Research involving 
human volunteers specifies 26 distinct concepts which needs to be shared during the 
Informed Consent process (APPENDIX I).  
A generic questionnaire was then developed based on ICH: Guideline 5 to test the 
volunteer’s comprehension of these various concepts. These questionnaires were 
multiple choice with four possible responses to each question. Comprehension of the 
following concepts was tested: 
1. Voluntary participation 
2. Compensation 
3. Withdrawal consequence 
4. Study versus treatment 
5. Study administration 
6. Randomization and placebo (study methodology) 
7. Side effects 
8. Volunteer protection (maintaining volunteer anonymity) 
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Hochhauser et.al. 200413 pointed out that since multiple choice questions include the 
correct answer among the incorrect alternatives; they measure recognition, not recall. In 
this project, the problem was addressed by using the same term in different ways e.g.: 
 
The purpose of this trial is to establish: 
The difference between 
4 Acamprosate calcium 
capsule products 
If the product to be 
tested (Acamprosate 
calcium) is not safe 
To prove that 
Acamprosate calcium is 
the best 
To prove that 
Acamprosate needs to 
be used in conjunction 
with Besobrial 
A □ 
 
B □ 
 
C □ 
 
D □ 
 
Figure 5: Example: masking of correct answer 
Each questionnaire was then modified according to each specific trial based on the 
study specific PIL/ICD for the applicable trial and consisted out of 25 questions: 
Informed Consent Questionnaire 
Instructions: 
This questionnaire is intended to establish your understanding of the clinical trial that you are 
enrolling in. It will NOT affect your eligibility to enroll into the study. 
The questionnaire is anonymous- please DO NOT write your name (or any part of it) on the 
questionnaire 
Please tick the correct answer with a “x” 
Thank you for completing the questionnaire 
 
 
 
 
 
 DEMOGRAPHIC INFORMATION: 
 
 Questionnaire Number: 
 
0001 
 
 Highest level of Education: 
 
Primary school 
 
High school 
 
Tertiary education 
 
Illiterate 
□ 
 
□ 
 
□ 
 
□ 
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 Race:  
 
Black 
 
White 
 
Coloured 
  
 Asian 
□ 
 
□ 
 
□ 
 
□ 
 
 Date of Birth:   
 
Day (dd) 
 
Month (mm) 
 
Year (yy) 
 
 
  
 Gender: 
 
Male 
 
Female 
□ 
 
□ 
 
 
1) Participation in this clinical trial is: 
 
Required by the 
Medicines 
Control Council 
(MCC) 
Voluntary Required by the sponsoring company 
Required by South-
African government 
□ 
 
□ 
 
□ 
 
□ 
 
 
2) If you withdraw from the clinical trial you will lose the following benefits you would 
otherwise be entitled to: 
 
Partial 
compensation 
All compensation Follow-up care/visits None 
□ 
 
□ 
 
□ 
 
□ 
 
 
3) The purpose of this trial is to establish: 
 
If the product to 
be tested (XXX) 
is the same as 
what is currently 
available on the 
market (XXX) 
If the product to be 
tested (XXX) is  not 
the same as what is 
currently available on 
the market (XXX) 
To prove that (XXX)  is 
the best A & C 
□ 
 
□ 
 
□ 
 
□ 
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4) The following staff will know which volunteers has received either (XXX) or (XXX): 
 
Clinic staff only Laboratory staff only Both clinic staff and 
Laboratory staff 
Nobody 
□ 
 
□ 
 
□ 
 
□ 
 
 
5) What is the duration of this study? 
 
3 weeks (19 
days) 
6 weeks (40 days) 4 weeks (26 days) 8 weeks (53 days) 
□ 
 
□ 
 
□ 
 
□ 
 
 
6) You will be compensated for your participation in the following way: 
 
R1980 R1980 and petrol 
money 
Food, drink and 
accommodation 
None, participation is 
voluntary 
□ 
 
□ 
 
□ 
 
□ 
 
 
7) After the trial: 
 
You will have to 
read the 
newspaper to get 
the results 
The results will be 
broadcasted on T.V. 
You will be informed of 
all findings related to 
your individual case 
You will be informed in 
writing about the 
results of the trial 
□ 
 
□ 
 
□ 
 
□ 
 
 
8) You are entitled to: 
 
Nothing- you 
have been paid  
The right of free 
speech 
The right of freedom of 
association 
The right of access to 
your data 
□ 
 
□ 
 
□ 
 
□ 
 
 
9) You may experience: 
 
Vomiting Headache Ear Ache Sedation, Drowsiness 
and a drugged feeling 
□ 
 
□ 
 
□ 
 
□ 
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10) As a result of your participation, you will:  (any benefits) 
 
Receive the 
newest care 
available 
Not have access to a 
Doctor 
Have a complete 
medical evaluation 
A and C 
□ 
 
□ 
 
□ 
 
□ 
 
 
 
11) As a result of this study: 
 
(XXX)  might be 
cured 
The (XXX) will not 
deteriorate as quickly 
The transmission of 
(XXX)  may be 
stopped 
A, B and C 
□ 
 
□ 
 
□ 
 
□ 
 
 
12) After the study you will  
 
Receive 
medication free of 
charge for three 
years 
Be phoned to 
participate in the 
follow-up study 
Follow-up 
investigations will be 
conducted within 72 
hours 
Not be able to contract 
(XXX) 
□ 
 
□ 
 
□ 
 
□ 
 
 
 
13) Currently, the following alternative treatment is available for your condition: 
 
Herbal 
medication 
Physiotherapy Following a specific 
diet 
Surgery 
□ 
 
□ 
 
□ 
 
□ 
 
 
14) Your privacy will be protected in the following way: 
 
Your telephone 
number will not 
be recorded 
anywhere at all 
Only your participant 
number will be used 
during analysis 
No other staff (other 
than the trial staff) will 
have access to your 
personal details 
B & C 
□ 
 
□ 
 
□ 
 
□ 
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15) Any personal results from this study 
 
Will not be 
communicated to 
anybody without 
your permission 
Will be communicated 
to your next of kin only 
Will be communicated 
to your insurance 
company 
Will be communicated 
to anybody who needs 
to know 
□ 
 
□ 
 
□ 
 
□ 
 
 
16) This study is sponsored by: 
 
GSK Novartis CH Aventis (XXX)  Limited 
□ 
 
□ 
 
□ 
 
□ 
 
 
17) Any records/data collected from you during the course of this study will 
 
Be made 
available for all 
follow-up studies 
as well 
Will not be used for 
any other purpose 
other than this study 
Will be used to 
develop training 
material 
Will be used to collect 
national statistics 
□ 
 
□ 
 
□ 
 
□ 
 
 
18) After the clinical trial, your biological samples (i.e. blood or urine) will be: 
 
Stored for three 
years 
Stored for 15 years Destroyed Returned to you 
□ 
 
□ 
 
□ 
 
□ 
 
 
 
19) A commercial product will be developed from your biological sample: 
 
True False 
□ 
 
□ 
 
 
20) The doctor involved in the study will be acting as: 
 
Your physician The Investigator The Investigator and 
your physician 
None 
□ 
 
□ 
 
□ 
 
□ 
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21) It is the investigator’s responsibility to 
 
Provide only 
(XXX)  related 
care 
Protect life and health Protect, life, health 
and privacy 
Protect, life, health, 
dignity and privacy 
□ 
 
□ 
 
□ 
 
□ 
 
 
22) Should you experience any adverse effects due to your participation to this study, 
you will: 
 
Receive medical 
care free of 
charge until you 
are healthy again 
Have to pay for 10% of 
your medical care 
Your medical aid will 
have to pay for your 
medical care 
Receive nothing 
□ 
 
□ 
 
□ 
 
□ 
 
 
23) Should you die or be disabled as a result of your participation in this study, your 
family or dependants will receive: 
 
R100 000 from 
the Medicines 
Control Council 
(MCC) 
No compensation R10 000 from (XXX) A & C 
□ 
 
□ 
 
□ 
 
□ 
 
 
24) The right to compensation is legally guaranteed: 
 
True False 
□ 
 
□ 
 
 
 
25) The protocol for this study has been approved by the Ethics Committee: 
 
True False 
□ 
 
□ 
 
 
2.6 Presentation 
 
Colourful, descriptive, visual presentations were developed and were based on both the 
PIL/ ICD for the respective studies as well as Guideline 5 of the International Ethical 
Guidelines for Biomedical Research involving human volunteers.  The presentations 
 Page 22  
    
 
were standard across the clinical trials with modifications made as applicable to each 
trial (refer to APPENDIX III). 
 
The presentations were facilitated by the trial physicians. 
 
2.7 Recruitment 
 
As the FARMOVS/Parexel clinic is situated on the campus grounds of the University 
of the Free state, volunteers at this clinic consist mainly of students attending the 
University. Volunteers with a different demographic composition (e.g. volunteers >40 
years of age) do occasionally also participate in the clinical trials conducted at this site. 
 
For the purposes of this project, all volunteers (regardless of age, level of education, 
race or gender) who were being screened for various trials at FARMOVS/Parexel were 
invited to participate.  
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CHAPTER 3: RESULTS 
 
3.1 Results 
 
In total, 85 volunteer records were evaluated during the statistical analysis process: 
● Read PIL/ ICD only (Group 1):     n = 28 (32.94%) 
● Read PIL/ ICD and Q&A session (Group 2):   n = 21 (24.71%) 
● Read PIL/ ICD and presentation (Group 3):   n = 17 (20.00%) 
● Read PIL/ ICD, presentation and Q&A session (Group 4): n = 19 (22.35%). 
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Figure 6: Number of questionnaires collected 
 
3.1.1 Objective 1: Compare the efficiency of data transfer to volunteers enrolled on a 
clinical trial by assessing their comprehension of clinical trial concepts 
 
The results of the volunteers that completed the questionnaire after participating in the 
protocols (group 1, 2, 3 and 4) can be summarized as follows: 
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3.1.1.1 Categorical Variables 
 
Table 1: Categorical Variables by Group 
 Group 1* 
n (%) 
Group 2* 
n (%) 
Group 3* 
n (%) 
Group 4* 
n (%) 
Total 
n (%) 
Summary of PIL/ ICD 
groups 
28 (32.94) 21 (24.71) 17 (20.00) 19 (22.35) 85 (100.00) 
Highest level of education 
   High school 
   Tertiary education 
 
11 (39.29) 
17 (60.71) 
 
11 (52.38) 
10 (47.62) 
 
7 (41.18) 
10 (58.82) 
 
7 (36.84) 
12 (63.16) 
 
36 (42.35) 
49 (57.65) 
Race 
   Black 
   White 
 
 1 (3.57) 
27 (96.43) 
 
2 (9.52) 
19 (90.48) 
 
1 (5.88) 
16 (94.12) 
 
6 (31.58) 
13 (68.42) 
 
10 (11.76) 
75 (88.24) 
Gender 
   Male  
   Female 
 
14 (50.00) 
14 (50.00) 
 
11 (52.38) 
10 (47.62) 
 
16 (94.12) 
1 (5.88) 
 
15 (78.95) 
4 (21.05) 
 
56 (65.88) 
29 (34.12) 
Question 1 
   A 
   B (correct answer) 
   C 
   D 
   Not answered/Don’t know   
 
 1 (3.57) 
25 (89.29) 
0 (0.00) 
1 (3.57) 
1 (3.57) 
 
 1 (4.76) 
20 (95.24) 
0 (0.00) 
0 (0.00) 
0 (0.00) 
 
0 (0.00) 
17 (100.00) 
0 (0.00) 
0 (0.00) 
0 (0.00) 
 
0 (0.00) 
18 (94.74) 
0 (0.00) 
0 (0.00) 
1 (5.26) 
 
2 (2.35) 
80 (94.12) 
0 (0.00) 
1 (1.18) 
2 (2.35) 
Question 2 
   A 
   B 
   C 
   D (correct answer) 
   Not answered/Don’t know   
 
11 (39.29) 
11 (39.29) 
0 (0.00) 
4 (14.29) 
2 (7.14) 
 
10 (47.62) 
3 (14.29) 
1 (4.76) 
5 (23.81) 
2 (9.52) 
 
11 (64.71) 
0 (0.00) 
0 (0.00) 
4 (23.53) 
2 (11.76) 
 
8 (42.11) 
5 (26.32) 
0 (0.00) 
3 (15.79) 
3 (15.79) 
 
40 (47.06) 
19 (22.35) 
1 (1.18) 
16 (18.82) 
9 (10.59) 
Question 3 
   A (correct answer) 
   B 
   C 
   D 
   Not answered/Don’t know   
 
19 (67.86) 
2 (7.14) 
2 (7.14) 
2 (7.14) 
3 (10.71) 
 
16 (76.19) 
0 (0.00) 
1 (4.76) 
1 (4.76) 
3 (14.29) 
 
17 (100.00) 
0 (0.00) 
0 (0.00) 
0 (0.00) 
0 (0.00) 
 
17 (89.47) 
0 (0.00) 
1 (5.26) 
1 (5.26) 
0 (0.00) 
 
69 (81.18) 
2 (2.35) 
4 (4.71) 
4 (4.71) 
6 (7.06) 
Question 4 
   A (correct answer) 
   B 
   C 
   D 
   Not answered/Don’t know   
 
3 (10.71) 
3 (10.71) 
18 (64.29) 
2 (7.14) 
2 (7.14) 
 
6 (28.57) 
0 (0.00) 
9 (42.86) 
4 (19.05) 
2 (9.52) 
 
5 (29.41) 
2 (11.76) 
9 (52.94) 
0 (0.00) 
1 (5.88) 
 
4 (21.05) 
3 (15.79) 
8 (42.11) 
3 (15.79) 
1 (5.26) 
 
18 (21.18) 
8 (9.41) 
44 (51.76) 
9 (10.59) 
6 (7.06) 
Question 5 
   A 
   B (correct answer) 
   C 
   D 
   Not answered/Don’t know   
   
1 (3.57) 
10 (35.71) 
15 (53.57) 
1 (3.57) 
1 (3.57) 
 
3 (14.29) 
15 (71.43) 
0 (0.00) 
1 (4.76) 
2 (9.52) 
 
1 (5.88) 
14 (82.35) 
2 (11.76) 
0 (0.00) 
0 (0.00) 
 
1 (5.26) 
16 (84.21) 
2 (10.53) 
0 (0.00) 
0 (0.0) 
 
6 (7.06) 
55 (64.71) 
19 (22.35) 
2 (2.35) 
3 (3.53) 
* Group 1 = Read PIL/ ICD only, Group 2 = Read PIL/ ICD and Q&A session, Group 3 = Read PIL/ ICD and 
presentation, Group 4 = Read PIL/ ICD, presentation and Q&A session 
 
Sixty one percent (61%) of volunteers in group 1, 48% of volunteers in group 2, 59% of 
volunteers in group 3 and 4, have had a tertiary education. In total, 58% of volunteers have 
had tertiary education. Thirty nine percent (39%) of subjects in group 1, 52% of subjects in 
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group 2, 41% of volunteers in group 3 and 37% of volunteers in group 4 had high school 
education. In total, 42% of the volunteers had high school education. 
 
Ninety six percent (96%) of volunteers in group 1, 90% of volunteers in group 2, 94% in 
group 3 and 68% of volunteers in group 4 were white. In total, 88% of the volunteers were 
white. Four percent (4%) of volunteers in group 1, 10% of volunteers in group 2, 6% of 
volunteers in group 3 and 32% of volunteers in group 4 were black. In total, 12% of the 
volunteers were black. 
 
In total, 34% of the volunteers were female of which 50% were in group 1, 48% were in 
group 2, 6% were in group 3 and 21% were in group 4. Sixty six percent of the total 
volunteers were male of which 50% were in group 1, 52% were in group 2, 94% were in 
group 3 and 79% were in group 4.  
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Table 1: Categorical Variables by Group (continued) 
 Group 1* 
n (%) 
Group 2* 
n (%) 
Group 3* 
n (%) 
Group 4* 
n (%) 
Total 
n (%) 
Summary of PIL/ ICD 
methods 
28 (32.94) 21 (24.71) 17 (20.00) 19 (22.35) 85 (100.00) 
Question 6 
   A (correct answer) 
   B 
   C 
   D 
   Not answered/Don’t know   
 
26 (92.86) 
1 (3.57) 
0 (0.00) 
0 (0.00) 
1 (3.57) 
 
20 (95.24) 
0 (0.00) 
0 (0.00) 
0 (0.00) 
1 (4.76) 
 
17 (100.00) 
0 (0.00) 
0 (0.00) 
0 (0.00) 
0 (0.00) 
 
19 (100.00) 
0 (0.00) 
0 (0.00) 
0 (0.00) 
0 (0.00) 
 
82 (96.47) 
1 (1.18) 
0 (0.00) 
0 (0.00) 
2 (2.35) 
Question 7 
   A 
   B 
   C (correct answer) 
   D 
   Not answered/Don’t know   
 
0 (0.00) 
0 (0.00) 
20 (71.43) 
4 (14.29) 
4 (14.29) 
 
0 (0.00) 
0 (0.00) 
15 (71.43) 
2 (9.52) 
4 (19.05) 
 
0 (0.00) 
0 (0.00) 
15 (88.24) 
2 (11.76) 
0 (0.00) 
 
0 (0.00) 
0 (0.00) 
18 (94.74) 
1 (5.26) 
0 (0.00) 
 
0 (0.00) 
0 (0.00) 
68 (80.00) 
9 (10.59) 
8 (9.41) 
Question 8 
   A 
   B 
   C 
   D (correct answer) 
   Not answered/Don’t know   
 
2 (7.14) 
5 (17.86) 
1 (3.57) 
18 (64.29) 
2 (7.14) 
 
6 (58.57) 
2 (9.52) 
0 (0.00) 
11 (52.38) 
2 (9.52) 
 
4 (23.53) 
4 (23.53) 
0 (0.00) 
7 (41.18) 
2 (11.76) 
 
2 (10.53) 
3 (14.79) 
0 (0.00) 
12 (63.16) 
2 (10.53) 
 
14 (16.47) 
14 (16.47) 
1 (1.18) 
48 (56.47) 
8 (9.41) 
Question 9 
   A 
   B 
   C 
   D (correct answer) 
   Not answered/Don’t know   
 
0 (0.00) 
8 (28.57) 
0 (0.00) 
10 (35.71) 
10 (35.71)  
 
1 (4.76) 
0 (0.00) 
0 (0.00) 
18 (85.71) 
2 (9.52) 
 
1 (5.88) 
3 (17.65) 
0 (0.00) 
12 (70.59) 
1 (5.88) 
 
0 (0.00) 
1 (5.26) 
0 (0.00) 
17 (89.47) 
1 (5.26) 
 
2 (2.35) 
12 (14.12) 
0 (0.00) 
57 (67.06) 
14 (16.47) 
Question 10 
   A 
   B 
   C (correct answer) 
   D 
   Not answered/Don’t know   
 
6 (21.43) 
0 (0.00) 
18 (64.29) 
0 (0.00) 
4 (14.29) 
 
4 (19.05) 
0 (0.00) 
15 (71.43) 
1 (4.76) 
1 (4.76) 
 
2 (11.76) 
0 (0.00) 
14 (82.35) 
0 (0.00) 
1 (5.88) 
 
1 (5.26) 
0 (0.00) 
15 (78.95) 
0 (0.00) 
3 (15.79) 
  
13 (15.29) 
0 (0.00) 
62 (72.94) 
1 (1.18) 
9 (10.59) 
* Group 1 = Read PIL/ ICD only, Group 2 = Read PIL/ ICD and Q&A session, Group 3 = Read PIL/ ICD and 
presentation, Group 4 = Read PIL/ ICD, presentation and Q&A session 
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Table 1: Categorical Variables by Group (continued) 
 Group 1* 
n (%) 
Group 2* 
n (%) 
Group 3* 
n (%) 
Group 4* 
n (%) 
Total 
n (%) 
Summary of PIL/ ICD 
methods 
28 (32.94) 21 (24.71) 17 (20.00) 19 (22.35) 85 (100.00) 
Question 11 
   A 
   B (correct answer) 
   C 
   D 
   Not answered/Don’t know   
 
0 (0.00) 
16 (57.14) 
1 (3.57) 
8 (28.57) 
3 (10.71) 
 
0 (0.00) 
13 (61.90) 
0 (0.00) 
6 (28.57) 
2 (9.52) 
 
0 (0.00) 
 11 (64.71) 
0 (0.00) 
5 (29.41) 
1 (5.88) 
 
3 (15.79) 
7 (36.84) 
1 (5.26) 
7 (36.84) 
1 (5.26) 
 
3 (3.53) 
47 (55.29) 
2 (2.35) 
26 (30.59) 
7 (8.24) 
Question 12 
   A 
   B 
   C (correct answer) 
   D 
   Not answered/Don’t know   
 
0 (0.00) 
7 (25.00) 
18 (64.29) 
0 (0.00) 
3 (10.71) 
 
0 (0.00) 
3 (14.29) 
15 (71.43) 
0 (0.00) 
3 (14.29) 
 
0 (0.00) 
2 (11.76) 
15 (88.24) 
0 (0.00) 
0 (0.00) 
 
0 (0.00) 
5 (26.32) 
13 (68.42) 
0 (0.00) 
1 (5.26) 
 
0 (0.00) 
17 (20.00) 
61 (71.76) 
0 (0.00) 
7 (8.24) 
Question 13 
   A 
   B 
   C (correct answer)  
   D 
   Not answered/Don’t know   
 
0 (0.00) 
0 (0.00) 
25 (89.29) 
2 (7.14) 
1 (3.57) 
 
 1 (4.76) 
0 (0.00) 
16 (76.19) 
2 (9.52) 
2 (9.52) 
 
0 (0.00) 
0 (0.00) 
16 (94.12) 
1 (5.88) 
0 (0.00) 
 
0 (0.00) 
0 (0.00) 
14 (73.68) 
2 (10.53) 
3 (15.79) 
 
1 (1.18) 
0 (0.00) 
71 (83.53) 
7 (8.24) 
6 (7.06) 
Question 14 
   A 
   B (correct answer) 
   C 
   D 
   Not answered/Don’t know   
 
 
4 (14.29) 
19 (67.86) 
5 (17.86) 
0 (0.00) 
0 (0.00) 
 
 
1 (4.76) 
15 (71.43) 
2 (9.52) 
0 (0.00) 
3 (14.29) 
 
0 (0.00) 
13 (76.47) 
3 (17.65) 
0 (0.00) 
1 (5.88) 
 
 
0 (0.00) 
13 (68.42) 
5 (26.32) 
0 (0.00) 
1 (5.26) 
 
5 (5.88) 
60 (70.59) 
15 (17.65) 
0 (0.00) 
5 (5.88) 
      
Question 15 
   A (correct answer) 
   B 
   C 
   D 
   Not answered/Don’t know   
 
22 (78.57) 
1 (3.57) 
1 (3.57) 
4 (14.29) 
0 (0.00) 
 
17 (80.95) 
1 (4.76) 
0 (0.00) 
1 (4.76) 
2 (9.52) 
 
11 (64.71) 
1 (5.88) 
0 (0.00) 
4 (23.53) 
1 (5.88) 
 
17 (89.47) 
0 (0.00) 
0 (0.00) 
1 (5.26) 
1 (5.26) 
 
67 (78.82) 
3 (3.53) 
1 (1.18) 
10 (11.76) 
4 (4.71) 
* Group 1 = Read PIL/ ICD only, Group 2 = Read PIL/ ICD and Q&A session, Group 3 = Read PIL/ ICD and 
presentation, Group 4 = Read PIL/ ICD, presentation and Q&A session 
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Table 1: Categorical Variables by Group (continued) 
 Group 1* 
n (%) 
Group 2* 
n (%) 
Group 3* 
n (%) 
Group 4* 
n (%) 
Total 
n (%) 
Summary of PIL/ ICD 
methods 
28 (32.94) 21 (24.71) 17 (20.00) 19 (22.35) 85 (100.00) 
Question 16 
   A 
   B 
   C (correct answer) 
   D 
   Not answered/Don’t know   
 
2 (7.14) 
1 (3.57) 
22 (78.57) 
1 (3.57) 
2 (7.14) 
 
0 (0.00) 
3 (14.29) 
13 (61.90) 
1 (4.76) 
4 (19.05) 
 
1 (5.88) 
0 (0.00) 
16 (94.12) 
0 (0.00) 
0 (0.00) 
 
2 (10.53) 
1 (5.26) 
15 (78.95) 
0 (0.00) 
1 (5.26) 
 
5 (5.88) 
5 (5.88) 
66 (77.65) 
2 (2.35) 
7 (8.24) 
Question 17 
   A 
   B (correct answer) 
   C 
   D 
   Not answered/Don’t know   
 
12 (42.86) 
6 (21.43) 
1 (3.57) 
8 (28.57) 
1 (3.57) 
 
8 (38.10) 
5 (23.81) 
1 (4.76) 
4 (19.05) 
3 (14.29) 
 
9 (52.94) 
6 (35.29) 
1 (5.88) 
1 (5.88) 
0 (0.00) 
 
6 (31.58) 
10 (52.63) 
0 (0.00) 
1 (5.26) 
2 (10.53) 
 
35 (41.18) 
27 (31.76) 
3 (3.53) 
14 (16.47) 
6 (7.06) 
Question 18 
   A 
   B (correct answer)  
   C 
   D 
   Not answered/Don’t know   
 
0 (0.00) 
0 (0.00)  
4 (14.29) 
23 (82.14) 
1 (3.57) 
 
1 (4.76) 
0 (0.00) 
1 (4.76) 
15 (71.43) 
4 (19.05) 
 
2 (11.76) 
0 (0.00) 
0 (0.00) 
15 (88.24) 
0 (0.00) 
 
0 (0.00) 
0 (0.00) 
2 (10.53) 
15 (78.95) 
2 (10.53) 
 
3 (3.53) 
0 (0.00) 
7 (8.24) 
68 (80.00) 
7 (8.24) 
Question 19 
   A 
   B (correct answer) 
   C 
   D 
   Not answered/Don’t know   
 
6 (21.43) 
20 (71.43) 
0 (0.00) 
0 (0.00) 
2 (7.14) 
 
3 (14.29) 
14 (66.67) 
 0 (0.00) 
0 (0.00) 
4 (19.05) 
 
2 (11.76) 
15 (88.24) 
0 (0.00) 
0 (0.00) 
0 (0.00) 
 
5 (26.32) 
13 (68.42) 
0 (0.00) 
0 (0.00) 
1 (5.26) 
 
16 (18.82) 
62 (72.64) 
0 (0.00) 
0 (0.00) 
7 (8.24) 
Question 20 
   A 
   B 
   C (correct answer) 
   D 
   Not answered/Don’t know   
 
6 (21.43) 
6 (21.43) 
13 (46.43) 
3 (10.71) 
0 (0.00) 
 
2 (9.52) 
12 (57.14) 
3 (14.29) 
1 (4.76) 
3 (14.29)  
 
3 (17.65) 
2 (11.76) 
9 (52.94) 
2 (11.76) 
1 (5.88) 
 
3 (15.79) 
4 (21.05) 
10 (52.63) 
1 (5.26) 
1 (5.26) 
 
14 (16.47) 
24 (28.24) 
35 (41.18) 
7 (8.24) 
5 (5.88) 
* Group 1 = Read PIL/ ICD only, Group 2 = Read PIL/ ICD and Q&A session, Group 3 = Read PIL/ ICD and 
presentation, Group 4 = Read PIL/ ICD, presentation and Q&A session 
 
 
 Page 29  
    
 
 
Table 1: Categorical Variables by Group (continued) 
 Group 1* 
n (%) 
Group 2* 
n (%) 
Group 3* 
n (%) 
Group 4* 
n (%) 
Total 
n (%) 
Summary of PIL/ ICD 
methods 
28 (32.94) 21 (24.71) 17 (20.00) 19 (22.35) 85 (100.00) 
Question 21 
   A 
   B 
   C 
   D (correct answer) 
   Not answered/Don’t know   
 
0 (0.00) 
0 (0.00) 
9 (32.14) 
17 (60.71) 
2 (7.14) 
 
1 (4.76) 
3 (14.29) 
1 (4.76) 
14 (66.67) 
2 (9.52) 
 
0 (0.00) 
1 (5.88) 
4 (23.53) 
12 (70.59) 
0 (0.00) 
 
1 (5.26) 
1 (5.26) 
3 (15.79) 
11 (57.89) 
3 (15.79) 
 
2 (2.35) 
5 (5.88) 
17 (20.00) 
54 (63.53) 
7 (8.24) 
Question 22 
   A (correct answer) 
   B 
   C 
   D 
   Not answered/Don’t know   
 
26 (92.86) 
1 (3.57) 
1 (3.57) 
0 (0.00) 
0 (0.00) 
 
16 (76.19) 
0 (0.00) 
1 (4.76) 
2 (9.52) 
2 (9.52) 
 
16 (94.12) 
1 (5.88) 
0 (0.00) 
0 (0.00) 
0 (0.00) 
 
15 (78.95) 
0 (0.00) 
2 (10.53) 
1 (5.26) 
1 (5.26) 
 
73 (85.88) 
2 (2.35) 
4 (4.71) 
3 (3.53) 
3 (3.53) 
Question 23 
   A 
   B 
   C 
   D (correct answer) 
   Not answered/Don’t know   
 
 
2 (7.14) 
4 (14.29) 
2 (7.14) 
19 (67.86) 
1 (3.57) 
 
2 (9.52) 
2 (9.52) 
0 (0.00) 
14 (66.67) 
3 (14.29) 
 
0 (0.00) 
1 (5.88) 
0 (0.00) 
16 (94.12) 
0 (0.00) 
 
2 (10.53) 
1 (5.26) 
0 (0.00) 
15 (78.95) 
1 (5.26) 
 
6 (7.06) 
8 (9.41) 
2 (2.35) 
64 (75.29) 
5 (5.88) 
Question 24 
   A (correct answer) 
   B 
   C 
   D 
   Not answered/Don’t know   
 
27 (96.43) 
1 (3.57) 
0 (0.00) 
0 (0.00) 
0 (0.00) 
 
16 (76.19) 
3 (14.29) 
0 (0.00) 
0 (0.00) 
2 (9.52) 
 
17 (100.00) 
0 (0.00) 
0 (0.00) 
0 (0.00) 
0 (0.00) 
 
13 (68.42) 
5 (26.32) 
0 (0.00) 
0 (0.00) 
1 (5.26) 
 
73 (85.88) 
9 (10.59) 
0 (0.00) 
0 (0.00) 
3 (3.53) 
Question 25 
   A (correct answer) 
   B 
   C 
   D 
   Not answered/Don’t know   
 
27 (96.43) 
0 (0.00) 
0 (0.00) 
0 (0.00) 
1 (3.57) 
 
19 (90.48) 
0 (0.00) 
0 (0.00) 
0 (0.00) 
2 (9.52) 
 
16 (94.12) 
1 (5.88) 
0 (0.00) 
0 (0.00) 
0 (0.00) 
 
17 (89.47) 
0 (0.00) 
0 (0.00) 
0 (0.00) 
2 (10.53) 
 
79 (92.94) 
1 (1.18) 
0 (0.00) 
0 (0.00) 
5 (5.88) 
* Group 1 = Read PIL/ ICD only, Group 2 = Read PIL/ ICD and Q&A session, Group 3 = Read PIL/ ICD and 
presentation, Group 4 = Read PIL/ ICD, presentation and Q&A session 
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3.1.1.2 Continuous Variables  
 
Table 2: Continuous Variables by Group 
 Group 1* Group 2* Group 3* Group 4* Total 
Age (years) 
   n 
   Mean 
   Median 
   SD  
   Minimum 
   Maximum 
   IQR 
 
28 
26.97 
21.45 
10.90 
18.29 
52.14 
20.08;33.25 
 
19 
27.37 
23.05 
10.68 
19.50 
56.60 
20.57;34.58 
 
16 
24.71 
22.35 
7.31 
18.70 
42.96 
20.16;23.25 
 
18 
25.11 
24.45 
4.81 
18.00 
33.74 
21.27;28.26 
 
81 
26.20 
22.21 
9.05 
18.00 
56.60 
20.49;28.01 
* Group 1 = Read PIL/ ICD only, Group 2 = Read PIL/ ICD and Q&A session, Group 3 = Read PIL/ ICD and 
presentation, Group 4 = Read PIL/ ICD, presentation and Q&A session 
Note: the ages of four volunteers were unknown 
 
The average age of all volunteers was 26 years. The youngest volunteer was 18 years old 
and the oldest volunteer was 57 years old.  
 
The average age for the volunteers in group 1 was 27 years of which the youngest 
volunteer was 18 years and the oldest volunteer was 52 years old.  
 
The youngest volunteer in group 2 was 20 years old and the oldest volunteer was 57 years 
old. Thus, the average age for volunteers in group 2 was 27 years old. 
 
Similarly, the youngest volunteer in group 3 was 19 years old and the oldest volunteer was 
43 years old. The average age of the volunteers in group 3 was 25 years old. 
 
Lastly, the youngest volunteer in group 4 was 18 years old and the oldest volunteer in 
group 4 was 34 years old. The average age of volunteers in group 4 was 26 years old.  
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3.1.1.3 Number of questions answered correctly 
 
Table 3: Number of questions answered correctly by Group 
 Group 1* 
n  
Group 2* 
n  
Group 3* 
n 
Group 4* 
n  
Total 
n 
Summary of PIL/ ICD 
methods 
28 21 17  19  85 
      
Nr of questions answered correctly 
   One (1) 0 1  0 0  1  
   Six (6) 0 1  0 0  1  
   Seven (7) 1  0 0 0  1  
   Nine (9) 0  0 0 1  1  
   Ten (10) 2  0 0 0  2  
   Eleven (11) 1  0 0 1  2  
   Twelve (12) 2  1  0 1 4  
   Thirteen (13) 1  0  0 0  1  
   Fourteen (14) 4  4  0 0  8  
   Fifteen (15) 1  0  0 1  2  
   Sixteen (16) 3  1  1  2  7  
   Seventeen (17) 4  2  5  4  15  
   Eighteen (18) 5 7  4  2  18  
   Nineteen (19) 2  1  4  4  11  
   Twenty (20) 2  2  1  1  6  
   Twenty one (21) 0  1  2  1  4  
   Twenty two (22) 0  0  0  1  1  
* Group 1 = Read PIL/ ICD only, Group 2 = Read PIL/ ICD and Q&A session, Group 3 = Read PIL/ ICD and 
presentation, Group 4 = Read PIL/ ICD, presentation and Q&A session 
 
Out of a total of 25 questions, the minimum number of questions answered correctly was 
one (recorded by one volunteer) and the maximum 22 (recorded by one volunteer). The 
mode (i.e. most common number of questions answered correctly) was 18 correct answers, 
recorded by 18 volunteers.  
 
The highest score (22 correct answers out of a potential of 25) was recorded in group 4 
(Read PIL/ ICD, presentation and Q&A session) and the lowest score (1 correct answer) 
was recorded by a volunteer who participated in group 2.  
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Figure 7: Frequency distribution of number of correct answers (n=85) 
 
The minimum number of questions answered correctly (out of a total of 25 questions) by 
volunteers in group 1 was seven (recorded by one volunteer) and the maximum 20 
(recorded by two volunteers). The mode (i.e. most common number of questions answered 
correctly) was 18 correct answers, recorded by 5 volunteers.  
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* Group 1 = Read PIL/ ICD only, Group 2 = Read PIL/ ICD and Q&A session, Group 3 = Read PIL/ ICD and 
presentation, Group 4 = Read PIL/ ICD, presentation and Q&A session 
Figure 8: Frequency distribution of number of correct answers by Group 
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Out of a total of 25 questions, the minimum number of questions answered correctly by 
volunteers in group 2 was one (recorded by one volunteer) and the maximum 21 (recorded 
by one volunteer). The mode (i.e. most common number of questions answered correctly) 
was 18 correct answers, recorded by 7 volunteers. 
 
The minimum number of questions answered correctly (out of a total of 25 questions) by 
volunteers in group 3 was sixteen (recorded by one volunteer) and the maximum 22 
(recorded by two volunteers). The mode (i.e. most common number of questions answered 
correctly) was 17 correct answers, recorded by 5 volunteers. 
 
Out of a total of 25 questions, the minimum number of questions answered correctly by 
volunteers in group 4 was nine (recorded by one volunteer) and the maximum 22 (recorded 
by one volunteer). The mode (i.e. most common number of questions answered correctly) 
was 17 and 19 correct answers, recorded by 4 volunteers each. 
 
3.1.2 Objective 2: Identifying the most effective PIL/ ICD method 
 
Table 4: Calculated mark (number of questions answered correctly) 
 Group 1* Group 2* Group 3* Group 4* Total 
   n 
   Mean 
   Median 
   SD  
   Minimum 
   Maximum 
 
28 
15.36 
16.00 
3.32 
7.00 
20.00 
 
21 
15.76 
18.00 
4.75 
1.00 
21.00 
 
17 
18.29 
18.00 
1.45 
16.00 
21.00 
 
19 
16.94 
17.00 
3.32 
9.00 
22.00 
 
85 
16.40 
17.00 
3.60 
1.00 
22.00 
 
* Group 1 = Read PIL/ ICD only, Group 2 = Read PIL/ ICD and Q&A session, Group 3 = Read PIL/ ICD and 
presentation, Group 4 = Read PIL/ ICD, presentation and Q&A session 
 
In Table 4, the “calculated mark” refers to the number of questions answered correctly out 
of a possible 25 questions. 
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Table 5: Calculated mark % ((calculated mark/25)*100) 
 Group 1* Group 2* Group 3* Group 4* Total 
   n 
   Mean 
   Median 
   SD  
   Minimum 
   Maximum 
 
28 
61.43 
64.00 
13.30 
28.00 
80.00 
 
21 
63.05 
72.00 
19.01 
4.00 
84.00 
 
17 
73.18 
72.00 
5.79 
64.00 
84.00 
 
19 
67.79 
68.00 
13.30 
36.00 
88.00 
 
85 
65.60 
68.00 
14.40 
4.00 
88.00 
 
* Group 1 = Read PIL/ ICD only, Group 2 = Read PIL/ ICD and Q&A session, Group 3 = Read PIL/ ICD and 
presentation, Group 4 = Read PIL/ ICD, presentation and Q&A session 
 
In Table 5, the “calculated mark %” = (calculated mark/25)*100. 
 
Based on the averages (means) of the “calculated mark” and “calculated mark %”, group 3 
scored the highest (68%), therefore, reading the PIL/ICD and attending a presentation, was 
the most effective way to transfer information regarding the PIL/ICD. 
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CHAPTER 4: DATA ANALYSIS AND DISCUSSION 
 
4.1 Data Analysis and Discussion 
 
The five questions that scored the highest average score in ascending order (i.e. that were 
answered correctly by the most volunteers) were: 
• Question 6: “You will be compensated for you participation in the following 
way” (correct response was the compensation for the study) 
• Question 1: “Participation in this trial is…” (correct response was 
“voluntary”) 
• Question 25: “The protocol for this study has been approved by an Ethics 
Committee” (correct response was “true”) 
• Question 22: “Should you experience any adverse effects due to your 
participation in this study, you will…” (correct response was “receive 
medical care free of charge until you are healthy again”) 
• Question 24: “The right to compensation is legally guaranteed” (correct 
response was “true”) 
 
Likewise, the questions that scored the lowest average score in ascending order (i.e. the 
questions that were answered incorrectly by the most volunteers) were: 
• Question 18: “After the clinical trial, your biological samples will be stored 
for…” (correct response was “15 years”) 
• Question 2: “If you withdraw from the clinical trial you will lose the following 
benefits you would otherwise be entitled to…” (correct response was “none”) 
• Question 4: “The following staff will know which volunteers has received xxx 
or xxx” (the correct response depended on the trial design i.e. double blind) 
• Question 17: “Any records/data collected from you during the course of this 
study will…” (correct response was “will not be used for any other purpose 
other than this study”) 
• Question 20: “The doctor involved in this study will be acting as…” (correct 
response was “the investigator and your physician”) 
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Table 6: Ranking of questions in order of number of correct answers (total) 
 Rank Question # Group 1 Group 2 Group 3 Group 4 
Combined 
Total 
1 Question 6 92.86 95.24 100 100 96.47 
2 Question 1 89.29 95.24 100 94.74 94.12 
3 Question 25 96.43 90.48 94.12 89.47 92.94 
4 Question 22 92.86 76.19 94.12 78.95 85.88 
5 Question 24 96.43 76.19 100 68.42 85.88 
6 Question 13 89.29 76.19 94.12 73.68 83.53 
7 Question 3 67.86 76.19 100 89.47 81.18 
8 Question 7 71.43 71.43 88.24 94.74 80 
9 Question 15 78.57 80.95 64.71 89.47 78.82 
10 Question 16 78.57 61.9 94.12 78.95 77.65 
11 Question 23 67.86 66.67 94.12 78.95 75.29 
12 Question 10 64.29 71.43 82.35 78.95 72.94 
13 Question 19 71.43 66.67 88.24 68.42 72.64 
14 Question 12 64.29 71.43 88.24 68.42 71.76 
15 Question 14 67.86 71.43 76.47 68.42 70.59 
16 Question 9 35.71 85.71 70.59 89.47 67.06 
17 Question 5 35.71 71.43 82.35 84.21 64.71 
18 Question 21 60.71 66.67 70.59 57.89 63.53 
19 Question 8 64.29 52.38 41.18 63.16 56.47 
20 Question 11 57.14 61.9 64.71 36.84 55.29 
21 Question 20 46.43 14.29 52.94 52.63 41.18 
22 Question 17 21.43 23.81 35.29 52.65 31.76 
23 Question 4 10.71 28.57 29.41 21.05 21.18 
24 Question 2 14.29 23.81 23.53 15.79 18.82 
25 Question 18 0 0 0 0 0 
 
4.1.1 Comprehension of clinical trial concepts 
The most insightful study regarding volunteer comprehension was conducted recently in 
Mali, West Africa8 whereby a questionnaire containing nine questions was administered to 
assess volunteer comprehension regarding the following topics: 
• Voluntary participation 
• Compensation 
• Withdrawal criteria 
• Withdrawal consequence 
• Study versus treatment 
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• Study administration 
• Randomization and placebo 
• Side effects 
• Lay scientific knowledge 
No other relevant data is available. The results of this project will be assessed according to 
the same concepts.  
 
4.1.1.1 Voluntary participation 
In total, 94% of the volunteers understood that their participation was voluntary (Question 
1). 
                     
Group 1 = Read PIL/ ICD only, Group 2 = Read PIL/ ICD and Q&A session, Group 3 = Read PIL/ ICD and 
presentation, Group 4 = Read PIL/ ICD, presentation and Q&A session   
percentage % = [number of correct answers/ group (n)] * 100 
 
Figure 9: Voluntary participation (Question 1) 
 
4.1.1.2 Compensation 
The concept of compensation is well understood as 96% of the volunteers answered this 
question correctly (Question 6). All the volunteers who participated in the groups utilizing 
visual aid (Group 3 and 4) answered the question regarding compensation consistently 
correct. 
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Group 1 = Read PIL/ ICD only, Group 2 = Read PIL/ ICD and Q&A session, Group 3 = Read PIL/ ICD and 
presentation, Group 4 = Read PIL/ ICD, presentation and Q&A session 
percentage % = [number of correct answers/ group (n)] * 100 
Figure 10: Compensation (Question 6) 
4.1.1.3 Withdrawal Consequence 
In total, only 19% of the volunteers answered the question regarding withdrawal 
consequence (Question 2) correctly with no clear advantage in a particular group. 
               
* Group 1 = Read PIL/ ICD only, Group 2 = Read PIL/ ICD and Q&A session, Group 3 = Read PIL/ ICD and 
presentation, Group 4 = Read PIL/ ICD, presentation and Q&A session, percentage % = [number of correct 
answers/ group (n)] * 100 
Figure 11: Withdrawal Consequence (Question 2) 
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4.1.1.4 Study versus treatment 
Eighty four percent (84%) of volunteers answered the question regarding the study versus 
alternative treatment (Question 13) correctly, also with no clear advantage in a particular 
group. 
                          
 * Group 1 = Read PIL/ ICD only, Group 2 = Read PIL/ ICD and Q&A session, Group 3 = Read PIL/ ICD 
and presentation, Group 4 = Read PIL/ ICD, presentation and Q&A session 
percentage % = [number of correct answers/ group (n)] * 100 
Figure 12: Study versus treatment (Question 13) 
 
4.1.1.5 Study Methodology 
The concepts of study administration was tested by asking questions regarding the 
volunteer’s duration of participation (Question 5), the identity of the sponsor (Question 16) 
and the duration of archiving (Question 18). Only 36% of the volunteers who had only read 
the PIL/ ICD could answer Question 5 correctly compared to 71% in group 2, 82% in 
group 3 and 84% of volunteers in group 4. Seventy seven percent (77%) of the volunteers 
could correctly identify the sponsor (Question 16) whereas 0% of the volunteers knew how 
long blood samples will be stored for (Question 18).  
 
Concepts regarding research/study methodology (Question 4) (e.g. double/single blinding) 
was not well understood as only 21% of the volunteers answered this question correctly. 
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* Group 1 = Read PIL/ ICD only, Group 2 = Read PIL/ ICD and Q&A session, Group 3 = Read PIL/ ICD and 
presentation, Group 4 = Read PIL/ ICD, presentation and Q&A session 
percentage % = [number of correct answers/ group (n)] * 100 
Figure 13: Study methodology (Question 4) 
 
4.1.1.6 Side effects 
After only reading the PIL/ ICD (Group 1), 64% of volunteers answered the question 
regarding side effects (Question 9) incorrectly and 37% of all volunteers answered the 
question regarding side effects (Question 9) incorrectly. 
                         
* Group 1 = Read PIL/ ICD only, Group 2 = Read PIL/ ICD and Q&A session, Group 3 = Read PIL/ ICD and 
presentation, Group 4 = Read PIL/ ICD, presentation and Q&A session, percentage % = [number of correct 
answers/ group (n)] * 100 
Figure 14: Side effects (Question 9) 
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4.1.1.7 Volunteer protection 
In total, 71% of volunteers understood how their data will be protected (Question 14). 
                       
* Group 1 = Read PIL/ ICD only, Group 2 = Read PIL/ ICD and Q&A session, Group 3 = Read PIL/ ICD and 
presentation, Group 4 = Read PIL/ ICD, presentation and Q&A session 
percentage % = [number of correct answers/ group (n)] * 100 
Figure 15: Volunteer protection (Question 14) 
 
 
4.1.2 Method of Data Transfer 
 
Although Group 3 (reading the PIL/ ICD and attending the presentation) showed a clear 
advantage, one should also consider that Group 4 (Reading the PIL/ ICD, attending the 
presentation and the question and answer session) delivered the second highest results.  
 
Therefore, the volunteers who attended the methods of data transfer which included a 
visual component (i.e. a presentation), scored on average higher than their counterparts 
who participated in Group 1 and Group 2 (i.e. methods that did not include a visual 
stimulus).  
 
It seems that the TGN 1412 trial was not conducted in vain. It prompted a number of new 
measures, suggestions and investigations from a variety of academic and regulatory sources 
in order to improve the safety of first-in-man studies. 
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At the time of writing this research report, the European Medicines Agency (EMEA) have 
released a guideline aimed specifically at improving the safety of Phase I trials. It is 
intended to help companies move potentially high risk medicines into early clinical studies. 
It covers quality aspects, non-clinical testing strategies and designs for first-in-man clinical 
trials, including the first dose, dose escalation, intervals between doses in healthy 
volunteers and risk management12,16.   
 
Although volunteer protection is a topic which has been debated, one can not ignore the 
benefit volunteers derive from their participation in clinical trials. It has been well observed 
that volunteers receiving placebo are generally doing better than their counterparts who are 
not participating in clinical trials. This may be contributed to the fact that they visit their 
clinicians more often, clinicians are more accessible and better compliance with their 
medication because they are aware that this is being checked. Therefore, the benefit to risk 
ratio should be thoroughly evaluated. 
 
In conclusion, there seems to be no clear answer as to how valid the Informed Consent 
process really is, but from these results one can conclude that by including a visual 
component to the informed consent process, the level of volunteer comprehension is 
increased (Group 3 and 4). 
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CHAPTER 5: CONCLUSION AND RECOMMENDATIONS 
 
5.1 Limitations 
 
True-false and multiple choice questions do represent a degree of limitation as volunteers 
can get a percentage of the questions correct by guessing. Volunteers can get 50% of true-
false questions correct by guessing and 25% of multiple choice questions containing 4 
possible answers13. 
   
Nonetheless, comprehension scores may still be higher on multiple choice questionnaires in 
comparison to when researchers ask the volunteers to tell them what they remembered 
about the trial. 
 
The sample size (20 questionnaires on each communication strategy, 80 questionnaires in 
total) was based upon the number of questionnaires that could realistically be collected 
rather than a formal statistical calculation. FARMOVS/PAREXEL conducts mainly Phase I 
and bioanalytical studies, therefore, the number of volunteers being screened was relatively 
small. Only descriptive statistics could be performed rather than a formal statistical 
comparison. 
 
To collect 80 questionnaires within the proposed timelines proved to be more challenging 
than originally anticipated as the Medicines Control Council (MCC) approval of trials was 
severely delayed. This resulted in trials either being cancelled or delayed. There were long 
periods of time when no screening for any trials could be conducted. 
 
A further limitation is that participants from the various indications (HIV, Asthma, 
Seizures and Alcohol Addiction) could not be distributed equally amongst the four 
investigational groups. This could however not be conducted differently as the project was 
approved by the facility’s management on condition that it did not add additional time to 
the normal functioning of the facility.  Further investigation is required to determine 
whether the indication of the clinical trial has an effect on the level of comprehension. 
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As the demographical (age, race and gender) composition of each group was unbalanced 
(due to the fact that screening volunteers were used), no conclusions can be made with 
respect to the demographical influence on the group scores. 
 
Although the average scores where higher in the groups that attended the presentations 
(Group 3 and 4), one must keep in mind that all four groups of volunteers had either high 
school or tertiary education (see table 1). The volunteers are thus familiar with 
presentations and may in turn, increase the level of comprehension.  
 
Therefore, it would be difficult to predict the general South-African population’s 
comprehension (and retention) of information shared via a presentation. 
 
 
Further investigation is thus needed into the development of valid informed consents in 
South-Africa since this project only included volunteers with an acceptable level of 
education, income and age and can therefore not be classified as “vulnerable”. 
 
5.2 Conclusions and Recommendation 
 
During this project, it was noted that volunteers understood clinical trial concepts better 
when visual aids were used during the informed consent process (Group 3 and Group 4): 
• Read PIL/ ICD only (Group 1): Mean calculated mark of 61.43% 
• Read PIL/ ICD and Q&A session (Group 2): Mean calculated mark of 63.05% 
• Read PIL/ ICD and presentation (Group 3): Mean calculated mark of 73.18% 
• Read PIL/ ICD, presentation and Q&A session (Group 4): Mean calculated mark 
of 67.79% 
 
From the above results one can conclude that volunteers who attended the methods of data 
transfer which included a visual component (i.e. a presentation) (Group 3 and 4), scored on 
average higher than their counterparts who participated in methods that did not include a 
visual stimulus (Group 1 and Group 2).  
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It is expected that a higher number of questionnaires would have demonstrated a more 
significant difference between the non-visual methods of data transfer (Group 1 and 2) and 
the visual methods (Group 3 and 4).  
Concepts that are not well understood within the South-African context are:  
• withdrawal consequence (Question 2),  
• methodology such as double-blind or single blind (Question 4),  
• duration of archiving (Question 18),  
• protection of records/ data (Question 17), and  
• the role of the investigator (Question 20) 
Following this project, the following recommendations can be made in order to improve 
volunteer comprehension of the concepts being shared with them during the informed 
consent process: 
• Repeat information as much as possible in as many different ways as possible 
• Depending on the demographic characteristics of the group visual aids generally 
increases comprehension and retention of information as it captivates the audience 
for longer periods of time and increases comprehension. 
• Keep the PIL/ICD as short as possible 
• More attention should be paid to ensure volunteer’s comprehension of withdrawal 
consequence as this was a concept that was not well understood 
• More attention should be paid to concepts regarding research methodology such as 
double-blind/single-blind etc. as this was a concept not well understood 
• Other concepts that are also not well understood include treatment alternatives, 
side-effects, duration of sample storage and the role of the investigator and should 
therefore receive more attention to improve volunteer comprehension 
• Do not assume that volunteers will have a good understanding of the clinical trial 
after only reading the PIL/ICD as volunteers who only read the PIL/ICD had a poor 
understanding of concepts such as the potential side effects relative to the other 
methods of data transfer. 
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However, as the calculated mark (%) in this project are lower than expected, it is 
imperative that further investigation should be conducted (especially in vulnerable 
populations).  
 
Despite increasing regulatory and ethical scrutiny, deficiencies still exist in volunteer 
comprehension of the research in which they participate, as well as differences in how 
comprehension is measured and assessed.  
 
Essentially, all methods are flawed since none of the groups scored 100%. Thus, every 
attempt should be made to improve the current process of informed consent. 
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APPENDIX I: Obtaining informed Consent: Essential Information 
 
Text of Guideline 5 of the International Ethical Guidelines for Biomedical Research 
involving human volunteers (International Conference of Harmonization (ICH). 
 
Before requesting a volunteer’s consent to participate in research, the investigator must 
provide the following information, in language or another form of communication that the 
volunteer can understand: 
1. that the volunteer is invited to participate in research, the reasons for considering 
the volunteer suitable for research and the participation is voluntary; 
2. that the volunteer is free to refuse to participate and will be free to withdraw from 
the research at any time without penalty or loss of benefits to which he or she will 
otherwise be entitled; 
3. the purpose of the research, the procedures to be carried out by the investigator and 
the volunteer, and an explanation of how the research differs from routine medical 
care; 
4. for controlled trials, an explanation of the features of the research design (e.g. 
randomization, double blinding), and that the volunteer will not be told of the 
assigned treatment until the trial has been completed and the blind has been broken; 
5. the expected duration of the volunteer’s participation (including number and 
duration of visits to the research centre and the total time involved) and the 
possibility of early termination of the trial or of the volunteer’s participation in it; 
6. whether money or other forms of material goods will be provided in return for the 
volunteer’s participation and, if so, the kind and amount; 
7. that, after the completion of the study, volunteers will be informed of the findings 
of the research in general, and volunteer volunteers will be informed of any finding 
that relates to their particular health status; 
8. that volunteers have the right of access to their data on demand, even if these data 
lack immediate clinical utility (unless the ethical review committee has approved 
temporary or permanent non-disclosure of data, in which case the volunteers should 
be informed of, and given, the reasons for such non-disclosure); 
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9. any foreseeable risks, pain or discomfort, or inconvenience to the volunteer (or 
others) associated with participation in the research, including risks to the health or 
well-being of a volunteer’s spouse or partner; 
10. the direct benefits, if any, expected to result to volunteers from participating in the 
research; 
11. the expected benefits of the research to the community or to society at large, or 
contributions to scientific knowledge; 
12. whether, when and how any products or interventions proven by the research to be 
safe and effective will be made available to volunteers after they have completed 
their participation in the research, and whether they will be expected to pay for 
them; 
13. any currently available alternative interventions or courses of treatment; 
14. the provisions that will be made to ensure respect for the privacy of volunteers and 
for the confidentiality of records in which volunteers are identified; 
15. the limits, legal or other, to the investigators’ ability to safeguard confidentiality, 
and the possible consequences of breaches of confidentiality; 
16. policy with regard to the use of results of genetic tests and familial genetic 
information, and the precautions in place to prevent disclosure of the results of a 
volunteer’s genetic tests to immediate family relatives or to others (e.g., insurance 
companies or employers) without the consent of the volunteer; 
17. the sponsors of the research, the institutional affiliation of the investigators, and the 
nature and sources of funding for the research; 
18. the possible research uses, direct or secondary, of the volunteer’s medical records 
and of biological specimens taken in the course of clinical care (see also Guidelines 
4 and 18 Commentaries); 
19. whether it is planned that biological specimens collected in the research will be 
destroyed at its conclusion, and, if not, details about their storage (where, how, for 
how long, and final disposition) and possible future use, and that volunteers have 
the right to decide about such future use, to refuse storage, and to have the material 
destroyed (see Guideline 4 Commentary); 
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20. whether commercial products may be developed from biological specimens, and 
whether the volunteer will receive monetary or other benefits from the development 
of such products; 
21. whether the investigator is serving only as an investigator or as both investigator 
and the volunteer’s physician; 
22. the extent of the investigator’s responsibility to provide medical services to the 
volunteer; 
23. that treatment will be provided free of charge for specified types of research-related 
injury or for complications associated with the research, the nature and duration of 
such care, the name of the organization or volunteer that will provide the treatment, 
and whether there is any uncertainty regarding funding of such treatment. 
24. in what way, and by what organization, the volunteer or the volunteer’s family or 
dependants will be compensated for disability or death resulting from such injury 
(or, when indicated, that there are no plans to provide such compensation); 
25. whether or nor, in the country in which the prospective volunteer is invited to 
participate in research, the right to compensation is legally guaranteed; 
26. That an ethical review committee has approved or cleared the research protocol. 
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APPENDIX II: Presentation 
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APPENDIX III: Study Specific Informed Consent Document 
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APPENDIX IV: WHEC Approval 
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APPENDIX V: UOFS Ethics Committee Approval 
 
